This product includes the webinar and SAM credit


Neal Lindeman, MD


Anna Yemelyanova, MD

The advent of targeted therapies based on predictive biomarkers has dramatically altered the role of the molecular pathologist in lung cancer patient care. This webinar reviews the new recommendations published in the revised 2018 CAP/IASLC/AMP lung cancer predictive biomarker guidelines (Lindeman et al.J Mol Diagn, 2018). This webinar, reviewing the evidence and logic behind the new recommendations, is designed for molecular pathologists, pathologists, oncologists, clinicians, trainees, and multidisciplinary tumor boards to help improve NSCLC patient care. Topics to be covered include recommendations regarding new predictive biomarkers; recommendations for testing for EGFR and ALK TKI resistance; and recommendations regarding new testing methodologies including the use of multiplexed genetic sequencing panels (e.g., NGS testing) to identify other treatment options beyond EGFRALK, and ROS1 as well as cell-free circulating DNA testing for EGFR resistance mutations. The revised 2018 CAP/IASLC/AMP lung cancer predictive biomarker guidelines will impact the daily practice of molecular pathologists and clinicians in the care of nearly 150,000 eligible lung cancer patients each year, regardless of whether in a community practice, a large reference lab, or an academic setting, and regardless of their level of expertise or experience.

Practice Guideline Available Here

Duration: 1 hr

Level of Instruction: Basic

Last day to purchase course and claim credit: December 31, 2020

Maximum SAM credit available: 1.0

Supported by an educational grant from AstraZeneca   

How to claim credit: To earn SAM credit, all learners must watch the webinar, achieve a minimum score of 80% on the online quiz, and complete an online survey. To access the quiz, click "Submit credit" on the course homepage or click on "My Credit" on the menu to the left and then "submit credit" for the appropriate course.

This course is approved by the American Board of Pathology for 1.0 SAM credits. Physicians should only claim credit commensurate with the extent of their participation in the activity. Participants must successfully complete the online modular exams (answering at least 80% of the questions in a topic module correctly).

SAM questions edited by: Catherine Cottrell, PhD

* You may not submit SAMs and CME/CMLE credit for the same content.

You may also be interested in:

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.


Course Information
Course Date:
May 29, 2018
Course Objectives
  • Review the new recommendations for lung cancer biomarker testing, their impact on patient care, and appropriate methods of testing (pre-analytic, analytic and post analytic actions).
  • Evaluate how the evidence published since the original 2013 guideline have been impacted by new observations and evidence since the first guideline.
  • Explain how molecular pathologists would utilize the recommendations in clinical practice using a case-based learning approach.
Pre-Test for Molecular Testing Guideline for Selection of Lung Cancer Patients - Revision (+SAM)
Molecular Testing Guideline for Selection of Lung Cancer Patients - Revision (+SAM)
Post-Test for Molecular Testing Guidelines for Selection of Lung Cancer Patients - Revision (+SAM)
QA Session
How to Claim SAM
Individual topic purchase: Selected
American Board of Pathology
Self-Assessment Module: 1.00
Lindeman (+SAM)
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00